Literature DB >> 27293808

Septic shock in the era of precision medicine.

Jordi Rello1, Francisco Valenzuela-Sánchez1.   

Abstract

Entities:  

Year:  2016        PMID： 27293808      PMCID： PMC4885986          DOI： 10.21037/jtd.2016.03.83

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 2.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Manu Shankar-Hari; Gary S Phillips; Mitchell L Levy; Christopher W Seymour; Vincent X Liu; Clifford S Deutschman; Derek C Angus; Gordon D Rubenfeld; Mervyn Singer
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 3.  Lactic acidosis.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

Review 4.  Personalized treatment of severe pneumonia in cancer patients.

Authors:  Ligia S C F Rabello; Thiago Lisboa; Marcio Soares; Jorge I F Salluh
Journal:  Expert Rev Anti Infect Ther       Date:  2015-09-07       Impact factor: 5.091

Review 5.  Precision medicine for the treatment of severe pneumonia in intensive care.

Authors:  Jordi Rello; Antonio Perez
Journal:  Expert Rev Respir Med       Date:  2016-02-09       Impact factor: 3.772

6.  Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial.

Authors:  François Lamontagne; Maureen O Meade; Paul C Hébert; Pierre Asfar; François Lauzier; Andrew J E Seely; Andrew G Day; Sangeeta Mehta; John Muscedere; Sean M Bagshaw; Niall D Ferguson; Deborah J Cook; Salmaan Kanji; Alexis F Turgeon; Margaret S Herridge; Sanjay Subramanian; Jacques Lacroix; Neill K J Adhikari; Damon C Scales; Alison Fox-Robichaud; Yoanna Skrobik; Richard P Whitlock; Robert S Green; Karen K Y Koo; Teddie Tanguay; Sheldon Magder; Daren K Heyland
Journal:  Intensive Care Med       Date:  2016-02-18       Impact factor: 17.440

Review 7.  The relevance of drug volume of distribution in antibiotic dosing.

Authors:  Marta Ulldemolins; Jordi Rello
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

Review 8.  Antibiotic dosing in multiple organ dysfunction syndrome.

Authors:  Marta Ulldemolins; Jason A Roberts; Jeffrey Lipman; Jordi Rello
Journal:  Chest       Date:  2011-05       Impact factor: 9.410

9.  Mean perfusion pressure deficit during the initial management of shock--an observational cohort study.

Authors:  Rakshit Panwar; Nicholas Lanyon; Andrew R Davies; Michael Bailey; David Pilcher; Rinaldo Bellomo
Journal:  J Crit Care       Date:  2013-07-10       Impact factor: 3.425
  9 in total
  3 in total

Review 1.  A path to precision in the ICU.

Authors:  David M Maslove; Francois Lamontagne; John C Marshall; Daren K Heyland
Journal:  Crit Care       Date:  2017-04-03       Impact factor: 9.097

Review 2.  Sepsis: A Review of Advances in Management.

Authors:  Jordi Rello; Francisco Valenzuela-Sánchez; Maria Ruiz-Rodriguez; Silvia Moyano
Journal:  Adv Ther       Date:  2017-10-11       Impact factor: 3.845

Review 3.  Current aspects in sepsis approach. Turning things around.

Authors:  F J Candel; M Borges Sá; S Belda; G Bou; J L Del Pozo; O Estrada; R Ferrer; J González Del Castillo; A Julián-Jiménez; I Martín-Loeches; E Maseda; M Matesanz; P Ramírez; J T Ramos; J Rello; B Suberviola; A Suárez de la Rica; P Vidal
Journal:  Rev Esp Quimioter       Date:  2018-06-25       Impact factor: 1.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.